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Howard Hughes Medical Institute, Department of Genetics, 
Yale University School of Medicine, New Haven, Connecticut 
I. INTRODUCTION 
H
eart disease and stroke are the number one and number three
leading causes of death in the United States, accounting for more 
than a third of all deaths annually. Epidemiologic studies have established 
a number of risk factors for these diseases, including hypertension, high 
cholesterol, diabetes mellicus, and smoking. Prospective randomized trials 
of blood pressure lowering, cholesterol reduction, and smoking cessation 
have established the causal relationship of these risk factors to disease, 
because modifying these parameters prevents adverse clinical outcomes, 
including death. 
In the case of cholesterol, initial therapeutic agents had modest 
cholesterol-lowering effects chat reduced risk of heart attack but did not 
reduce overall mortality. Understanding the cholesterol biosynthecic 
pathway ultimately led to identification of rate-limiting steps in the pathway 
and development of highly potent cholesterol-lowering agents, the HMG­
CoA reduccase inhibitors. These agents lower cholesterol far more than 
their predecessors and markedly reduce both morbidity and overall·mortal­
ity. These studies underscore the importance of identifying the right targets 
in the right pathways in order to achieve optimal clinical results. 
Hypertension is the most common disease of the industrialized world, 
affecting one billion people world-wide and more than 70% of the elderly 
population. Treatment of hypertension has clear benefit co reduce the 
incidence of stroke and heart attack (Multiple Risk Factor Intervention 
Trial Research Group, 1982; Medical Research Council Working Party, 
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1985). Nonetheless, the blood pressure reduction achieved with current 
single medications is relatively modest in most treated subjects; only a 
small minority of hypertensive individuals achieve the goals of blood 
pressure reduction, leaving considerable room for improvement in therapy. 
Efforts to improve therapy, however, have been complicated by a lack of 
understanding of the main pathways that determine long-term blood 
pressure homeostasis and the key points in these pathways that would 
represent the best therapeutic targets. This uncertainty arises from the 
complex physiologic regulation of blood pressure, with inputs from the 
brain, heart, adrenal, kidney, vasculature, and endocrine systems (Fig. 
3.1). Consequently, the field has been plagued with many proposals as to 
where primary abnormalities might lie with little substantiating data. 
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Fig. 3.1. Model of blood pressure homeostasis. The wiring diagram of a computer 
model of blood pressure homeostasis devised by Arthur Guyton. The model illustrates the 
many organs and physiologic systems chat have inpur inco blood pressure homeostasis. 
Reproduced with permission from the Annual Review of Physiology, Volume 34, copyright 
1972 by Annual Reviews, www.annualreviews.org. 
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II. GENETIC APPROACHES TO UNDERSTAND COMPLEX TRAITS 
In the setting of such complex systems biology, geneti� approaches 
have considerable merit. Most importantly, they can definitively settle 
the question of causality that commonly plagues analysis of complex 
systems. 
There are multiple approaches one might rake to this problem. We 
were initially inspired by genetic approaches in model organisms, in 
which complex systems like development have been effectively dissected 
by large-scale muragenic screens, looking for mutations char impart large 
effects in order to identify the key genes and pathways that affect the trait 
in question (Nusslein-Volhard and Wieschaus, 1980). This suggested a 
search not for common alleles in the general population char might impart 
incremental effects on the trait, bur for rare alleles with very large effects 
that should define the important underlying pathways that control the 
trait. While one cannot perform mutagenesis in humans, one can rake 
advantage of the presence of the more than 12 billion copies of the human 
genome in existence among the world's inhabitants. With a 3 billion base 
pair genome and reasonable estimates of the mutation frequency, muta­
tions altering virtually every base in the genome that are compatible with 
survival exist somewhere on the planet, and they come to medical atten­
tion. Owing to high rares of consanguinity in a number of cultures, even 
rare recessive alleles can be found in the homozygous state. 
These considerations motivated our efforts to systematically scour the 
globe for extreme outliers with either extremely high or extremely low 
blood pressure, followed by clinical investigation of the index case and 
the extended kindred to identify distinct physiologic features and to 
determine whether blood pressure or related endophenotypes show evi­
dence of Mendelian segregation. Among such families, mapping studies 
comparing the transmission of each chromosome segment to the inher­
tance of altered blood pressure can pinpoint the location of the underlying 
disease gene, and screening of genes in the linked interval can identify 
underlying functional mutations. Importantly, the typical occurrence of 
independent mutations among unrelated kindreds chat segregate with the 
trait and which show specificity for the trait settle the issue of causality, 
an important advantage. The demonstration of single gene mutations that 
impart large effects on blood pressure have the capacity to identify key 
rate-determining steps and pathways for the behavior of the overall system. 
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These sites represent logical points at which therapeutic intervention 
might have the greatest impact. Importantly, as for cholesterol homeosta­
sis, intervention at these rate-determining steps may have the greatest 
therapeutic impact in the general population, regardless of the presence 
or absence of mutations in this pathway. 
To date, we have used this approach to identify mutations in eight 
genes that raise blood pressure and another eight genes in which mutation 
lowers blood pressure. The most striking finding from these studies is 
that these genes define a final common pathway that regulates renal salt 
handling: Mutations that increase net renal salt reabsorption raise 
blood pressure, and mutations that reduce salt reabsorption lower blood 
pressure. 
III. RENAL SALT HOMEOSTASIS 
In order to understand the relationship between salt and blood pres­
sure, a basic knowledge of renal salt homeostasis is required. Every day 
the kidneys of a normal adult filtei: 170 liters of plasma containing 1.5 kg 
of salt. Consequently, on a typical Western 5-g salt diet, the kidneys must 
reabsorb all but about 0.5% of the filtered load of salt to maintain homeo­
stasis. The amount of water reabsorbed is precisely regulated to maintain 
a serum sodium concentration very close to 140 mM. As a consequence, 
increased salt reabsorption initially leads to higher plasma volume; con­
versely, reduced salt reabsorption results in lower plasma volume. 
The kidneys achieve salt homeostasis by a complex, integrated set of 
exchangers, cotransporters, and channels that act in distinct nephron seg­
ments (Fig. 3.2). Bulk reabsorption occurs proximally, with progressively 
smaller fractions reabsorbed in each subsequent nephron segment. About 
60% of the filtered sodium load of salt is reabsorbed by Na+/H+ exchange 
in the proximal tubule, 30% by the action of a Na+-K+-2ci- cotrans­
porter in the thick ascending limb of Henle, 7% by the action of a Na-Cl 
cotransporter in the distal convoluted tubule, and the last 2% by the 
action of the renal epithelial sodium channel (ENaC). Reabsorption of 
Na+ via ENaC is electrogenic, providing the electrical driving force to 
support either paracellular o- reabsorption or K+ and H+ secretion. 
The activity of this final channel, ENaC, is regulated by the renin­
angiotensin system. The renin-angiotensin system is activated when the 











Fig. 3.2. Elements contributing co renal sale homeostasis. A diagram of a nephron is 
shown. Sodium filtered at the glomerulus is reabsorbed by four major mediators distributed 
along the nephron as described in the text. Reabsorpcion of Na+ by che epithelial sodium 
channel in the distal nephron is regulated by the activity of the renin-angiocensin system 
via regulated production of the steroid hormone aldoscerone. 
kidney senses reduced chloride delivery to the thick ascending limb of 
Henle, resulting in secretion of the aspartyl protease renin by cells of the 
juxtaglomerular appratus. Renin cleaves the circulating protein angioten­
sinogen to angiotensin I, which is further cleaved by angiotensin convert­
ing enzyme to the active peptide hormone angiotensin II. Angiotensin II 
binds to specific receptors in the adrenal glomerulosa, which leads to 
increased secretion of the steroid hormone aldosterone; aldosterone binds 
to specific receptors in principal cells of the distal nephron, which ulti­
mately leads to increased activity of the epithelial sodium channel. 
The mutations our group has identified impart large effects on blood 
pressure and/ or related traits. In each case, families from around the world 
have been identified and clinically characterized, and disease-causing 
mutations have been identified. In nearly every case, biochemical and 
clinical studies have established the specific mechanisms by which muta­
tions increase or decrease renal salt reabsorption. 
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IV. MUTATIONS THAT RAISE BLOOD PRESSURE 
A. Glucocorticoid-Remediable Aldosteronism (GRA)
GRA is an autosomal dominant trait featuring early onset of severe 
hypertension (Sutherland et al., 1966). Physiologically, affected patients 
have elevated levels of aldosterone despite suppression of renin levels. 
Interestingly, aldosterone secretion in these patients is driven by adreno­
corticotropic hormone (ACTH), the normal secretagogue for cortisol, 
rather than angiotensin II. By investigation of families with GRA, we 
demonstrated that this disease is caused by a gene duplication produced 
by unequal crossing over between two genes involved in adrenal steroid 
biosynthesis (Fig. 3.3; Lifton et al., 1992a,b). One of these genes encodes 
aldosterone synthase, which is the rate-limiting step in aldosterone bio­
synthesis in the adrenal glomerulosa and whose expression is normally 
regulated by angiotensin II signaling. The other gene encodes steroid 11-
beta hydroxylase, which is employed in cortisol biosynthesis in adrenal 
fasciculata and whose expression is regulated by adrenocorticotropic 
Aldosterone synthase 
5' 3' 
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I 111 rnChimeric Gene 1 IP-hydroxy lase Fig. 3.3. The genetic basis of the hypertensive disease glucocorticoid-remediable aldo­steronism. Unequal crossing over between genes encoding aldosterone synthase and steroid 11-beta hydroxylase produces a chimeric gene duplication fusing 5' regulatory sequencesof 11-beta hydroxylase to coding sequences of aldosterone synthase. This leads to ectopicexpression of aldosterone synthase enzymatic activity in adrenal fasciculata under controlof ACTH.
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hormone (ACTH). These two genes have recently evolved from a common 
ancestor; they are tightly linked on chromosome 8 in head-to-tail configu­
ration and are 95% identical in DNA sequence. The chimeric gene dupli­
cations that cause GRA fuse ACTH-responsive regulatory elements from 
11-hydroxylase onto coding sequences that result in aldosterone synthase
enzymatic activity (Fig. 3.3). This results in expression of the rate-limiting
enzyme for aldosterone synthesis in the wrong tissue, the adrenal fascicu­
lata, under control of the wrong hormone, ACTH. At the expense of 
maintaining ACTH levels to support normal cortisol secretion, affected
subjects consequently have sustained aldosterone secretion.
This mutation results in hypertension by the following sequence: 
Chronic aldosterone secretion leads to increased sodium reabsorption 
via ENaC; water follows to maintain isotonicity of plasma, leading to 
increased intravascular volume; this increases venous blood return to the 
heart, and the cardiac stroke volume and cardiac output consequently 
increases; by Ohm's law, this increase in cardiac output results in elevated 
blood pressure. This elevation in blood pressure is sufficient to suppress 
the activity of the renin angiotensin system; however, this fails to reduce 
aldosterone secretion, since aldosterone secretion is now under control of 
ACTH. 
B. Mendelian Hypertension Exacerbated by Pregnancy
Aldosterone signals via the mineralocorticoid receptor, a member of 
the nuclear hormone receptor family. By investigation of a unique family 
with unexplained severe hypertension with suppressed renin and aldoste­
rone secretion, we defined a new disease, demonstrated that it was trans­
mitted as a simple autosomal dominant trait, and demonstrated that it is 
caused by gain of function mutation in the mineralocorticoid receptor 
(Geller et al., 2000). The disease-causing mutation is missense, and it lies 
in the ligand binding domain of the mineralocorticoid receptor, substitut­
ing leucine for a native serine in helix 5 (Fig. 3.4). Biochemical studies 
in mammalian cells demonstrated partial activation of the mutant recep­
tor in the absence of added steroid; more impressively, steroids such as 
progesterone that lack a 21-hydroxyl group, which normally bind but fail 
to activate the receptor, become very potent agonists for the mutant 
receptor. 
Molecular modeling followed by site-directed mutagenesis has shown 
that the disease-causing mutation creates a key van der Waals interaction 
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Fig. 3.4. Hypertension caused by mineralocorticoid receptor mutation. Molecular 
model of aldosterone binding to the mineralocorticoid receptor is shown. The wild-type 
receptor with Serine at position 810 is shown at right, and the mutant receptor with leucine 
at position 810 is shown at left. L810 is capable of a new van der Waals interaction with 
alanine 773 in helix 3, near the site where the 21-hydroxyl group of aldosterone interacts 
with asparagine 770. This new interaction eliminates the requirement for the steroid 21-
hydroxyl group, resulting in receptor activation by progesterone and other steroids. 
between helix 5 and helix 3 of the ligand binding domain. This new 
interaction replaces the requirement for an interaction between the steroid 
21-hydroxyl group and helix 3 of the receptor, allowing steroids lacking
chis moiety to become potent receptor agonises. These observations make
a clinical prediction: in normal pregnancy, progesterone levels rise 100-
fold; if progesterone is indeed an agonise for chis mutant receptor, women
harboring chis mutation should develop severe hypertension. This is
indeed the case. The five pregnancies among women harboring chis muta­
tion have been accompanied by the development of extreme hyperten­
sion, nece·ssicacing early delivery or termination of pregnancy. This is the
first demonstration of a molecular mechanism underlying this common
complication of pregnancy and demonstrate that it can arise from the
abnormal action of a normal hormone.
C. Liddle Syndrome
Downstream of the mineralocorticoid receptor lies its major target, the 
epithelial sodium channel (ENaC). ENaC is composed of homologous 
subunits encoded by three different genes, alpha, beta, and gamma. Muta­
tions in ENaC subunits cause another Mendelian form of hypertension 
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Fig. 3.5. Mutations in the epithelial sodium channel (ENaC) cause the hypertensive 
disease Liddle syndrome. Mutations that delete or modify the PPPXY motif in the cyto­
plasmic tail of the beta or gamma subunits of ENaC cause Liddle syndrome by impairing 
the clearance of ENaC from the cell surface via endocytosis through clathrin-coated pits. 
known as Liddle syndrome. This disease features early onset hypertension 
transmitted as an autosomal dominant trait; affected patients have hyper­
tension despite suppression of the renin-angiotensin system and reduced 
levels of aldosterone. By investigation of families with this disease, we 
have shown that Liddle syndrome is caused by mutations in the beta or 
gamma ENaC subunits (Fig. 3.5; Shimkets et al., 1994, Hansson et al., 
1995); disease-causing mutations eliminate or alter single amino acids in 
the cytoplasmic C-termini of these proteins. The target sequence for these 
mutations is a PPPXY segment shared by these two subunits (Schild et 
al., 1996). This shared sequence motif is required for the normal removal 
of ENaC from the cell surface by endocytosis via clathrin-coated pits 
(Shimkets et al., 1997). This sequence is recognized by 'WW domains of 
Nedd-4, a ubiquitin ligase, implicating Nedd-4 in this clearance mecha­
nism (Staub et al., 1996). These mutations thus result in a prolonged 
half-life and increased levels of ENaC at the cell surface (Shimkets et al., 
1997). These channels are active and mediate increased sodium reabsorp­
tion, thus feeding into the same final common pathway for hypertension 
as patients with GRA and mineralocorticoid receptor mutations. These 
findings establish that increased renal sodium reabsorption alone is suffi­
cient to produce hypertension in humans, independent of mineralocorti­
coid receptor action. 
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It is tempting to speculate char the clearance mechanism for ENaC 
discovered via Liddle syndrome is involved in the normal regulation of 
ENaC activity by aldosterone. Recent data supports chis notion, linking 
activity of an aldosterone-regulaced kinase, SGK, to regulation of Nedd-
4's activity on ENaC (Ichimura et al., 2005). 
D. Genetic Screening
With the identification of the molecular basis of these autosomal domi­
nant forms of hypertension, we have developed simple generic tests to 
identify patients with these diseases. The purposes of such testing are 
several, allowing determination of the prevalence of these diseases among 
the hypertensive population, permitting studies of the impact of these 
mutations on blood pressure and clinical outcomes in an unbiased fashion 
by the study of extended kindreds, and permitting specific therapy tai­
lored to the mutation among affected subjects. Over the last decade, we 
have screened over 1000 samples sent by physicians from around the 
world for evaluation of unexplained hypertension. Among these, we have 
identified 42 new kindred� with GRA and 12 new kindreds with Liddle 
syndrome, as well as over 200 additional affected subjects identified from 
their relationship to an affected index case. The strongest predictors of a 
positive test are onset of hypertension before the age of 20 and a first­
degree relative with the same finding; among such subjects, 25% have 
mutations in one of the above genes. 
From these studies, we have also shown that these genes on average 
impart a very large quantitative effect on blood pressure, approximating 
30 mm Hg in the case of GRA. This marked effect on blood pressure has 
important clinical consequences for affected patients: Patients with GRA 
have a dramatic increase in the risk of intracranial hemorrhage before the 
age of 45, most often due to rupture of aneurysms of the circle of Willis. 
Prospective screening of affected subjects has identified asymptomatic 
aneurysms char have resulted in premorbid surgical intervention. Identi­
fication of these patients has also permitted therapeutic intervention with 
agents tailored to the underlying primary abnormality. 
V. MUTATIONS THAT LOWER BLOOD PRESSURE 
We are equally interested in mutations chat lower blood pressure, 
because loss of function mutations chat reduce blood pressure may define 
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therapeutic targets at which pharmacologic inhibitors would have benefi­
cial blood-pressure-lowering effects. We have approached this problem 
by investigating newborns with life-threatening hypotension. 
A. Pseudohypoaldosteronism Type I (PHAI)
PHAI features severe hypotension in the neonatal period. There are 
autosomal recessive, autosomal dominant and sporadic forms (Hanukoglu, 
1991). Affected subjects have severe salt wasting despite marked ele­
vations in renin and aldosterone. In addition to salt wasting, they also have 
striking hyperkalemia and metabolic acidosis. These findings all point to 
defective Na+ reabsorption in the distal nephron, since impaired Na+ 
reabsorption at this site would be expected to impair secretion of K+ and 
protons. 
We have shown that the recessive form of this disease is caused by 
diverse loss of function mutations in subunits of ENaC, the same channel 
in which gain of function mutations cause Liddle syndrome (Fig. 3.6; 
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Fig. 3.6. Mutations in ENaC cause the hypotensive disease pseudohypoaldosteronism 
type I. Loss of function mutations in ENaC result in massive sale wasting leading co activa­
tion of the renin-angiotensin system. The loss of ENaC function prevents the increased 
aldosterone level from increasing Na+ reabsorption. Due co the loss of electrogenic Na+ 
reabsorption via ENaC, K+ and H+ secretion are also impaired, resulting in hyperkalemia 
and metabolic acidosis. 
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PHAI is caused by heterozygous loss of function mutations in the min­
eralocorticoid receptor (Geller et al., 1998). Most interestingly, while 
neonates with either form of PHAI can be gravely ill in the neonatal 
period, there are striking differences later in life. Patients with ENaC 
mutations remain extremely dependent upon massive salt supplementa­
tion and perpetual treatment to lower serum K+ levels. Mild intercurrent 
illness can be life-threatening due to impaired dietary salt intake. In con­
trast, patients with mineralocorticoid receptor mutations become asymp­
tomatic, usually after age 2, and as adults are entirely asymptomatic, with 
only a striking elevation in resting aldosterone levels as a biochemical 
mark of their underlying defect (Geller et al., in preparation). 
These findings have several important clinical implications. Most sig­
nificantly, they require a reconsideration of the long-held view that ENaC 
is wholly dependent upon aldosterone, and that on a typical 5-g salt diet, 
with suppression of the renin-angiotensin system, ENaC activity is dis­
pensable. The fact that patients missing EN aC require 20-30 g of salt per 
day to maintain a semblance of normal intravascular volume indicates the 
essential role of ENaC for normal.homeostasis. These observations under­
score the possibility of developing improved antihypertensive agents that 
target ENaC (see below). 
B. Gitelman Syndrome
The recognition that gain or loss offunction of ENaC lead to increased 
or reduced blood pressure prompted consideration of the phenotypes that 
might result from altered function of other mediators of renal salt reab­
sorption. These led to the consideration of Gitelman syndrome and 
Banter syndrome, two diseases featuring abnormalities in salt, potassium, 
pH, magnesium, and calcium homeostasis (Bettinelli et al., 1992). We 
showed thar- Gitelman syndrome is caused by recessive loss of function 
mutations in the thiazide-sensitive Na-Cl cotransporter of the renal distal 
convoluted tubule (NCC) (Simon et al., 1996a). This results in primary 
salt wasting, along with activation of the renin-angiotensin system, 
leading to increased ENaC activity, which, in turn, leads to hypokalemia 
and metabolic alkalosis (Fig. 3.7). In addition, these patients uniformly 
have both hypomagnesemia due to renal Mg2+ loss and hypocalciuria. 
These latter features are not readily explained from known physiology but 
indicate an essential requirement for NCC activity in the normal homeo­
stasis of Mg2+ and Ca2+. 
GENETIC DISSECTION OF HUMAN BLOOD PRESSURE VARIATION 83 
♦ReninNa+ c1· ! 
♦ 7% 1 ♦ AldosteroneI ' I 
Na-K-2CI I Na+ 2%} ♦Activity30% l+K+, H+ ♦ 
Low K+, Low H+
♦ Salt Wasting
Fig. 3.7. Mutations in the Na-Cl cotransporter (NCC) cause Gitelman syndrome. 
Loss of function mutations in NCC result in salt wasting and induction of the renin­
angiotensin system. This leads to a compensatory increase in Na+ reabsorption via ENaC, 
resulting in only modest reduction in blood pressure; the increased lumen-negative poten­
tial results in increased elecrrogenic drive for K+ and H+ secretion, leading to hypokalemia 
and metabolic alkalosis. 
We hypothesized that the relatively mild salt wasting seen in this disease 
should reduce blood pressure. This was tested by clinical investigation of 
200 members of an extended kindred segregating two identified NCC 
mutations. By genotyping kindred members, we were able to compare 
the blood pressures of family members harboring zero, one, or two mutant 
copies of the gene. The results demonstrated an average 8-mmHg reduc­
tion in systolic blood pressure among homozygous mutant subjects, with 
no reduction in blood pressure of heterozygotes. This reduction was 
highly significant but nonetheless was somewhat less than might have 
been anticipated. This led us to consider whether affected subjects might 
in some way be compensating for their inherited defect. One obvious 
means to achieve this would be to simply eat more salt. This was tested 
by measuring 24-hour urinary Na+ excretion, which in steady state is the 
best indicator of dietary salt intake. Interestingly, both the heterozygous 
and homozygous mutant subjects were found to consume markedly more 
salt than their wild-type relatives, indicating dietary compensation for the 
inherited renal defect (Cruz et al., 2001). 
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These findings have several interesting implications. First, they reveal 
the complexity of the relationship between salt intake and blood pressure. 
Epidemiologic studies over the last half-century have examined this rela­
tionship, but have struggled to provide generalizable conclusions (Taubes, 
1998). Kindreds such as this one provide suggestions as to why this rela­
tionship is so confounded. In this family, the individuals with the lowest 
blood pressure are those that are eating the most, not the least, salt. The 
recognition that primary renal salt wasting induces increased dietary salt 
consumption reveals the difficulty in demonstrating a simple relationship 
between salt intake and blood pressure. Second, these findings also make 
the interesting point that dietary taste for salt, which might have been 
considered a complex behavioral trait, can be determined by the activity 
of a protein in the kidney. 
C. Bartter Syndrome
The related disease Bartter syndrome features a typically far more severe 
form of salt wasting that has high morbidity and mortality in the neonatal 
period. Affected subjects are n0w recognized to have, in addition to 
hypokalemia and metabolic alkalosis, mild to severe hypercalciuria, with 
a substantial fraction developing nephrocalcinosis resulting in renal 
failure. This disease proves to result from a failure of salt reabsorption in 
the renal thick ascending limb of Henle (T AL) and define the pathway 
by which salt traverses the TAL (Fig. 3.8). To date, loss offunction muta­
tions in four genes have been identified that result in related phenotypes. 
One of these, the Na-K-2Cl cotransporter encoded by NKCC2, mediates 
the entry of salt from the lumen into the epithelium of this nephron 
segment; homozygous loss of function mutations in this gene are one 
cause of Bartter syndrome (Simon et al., 19966). 
Potassium entering epithelial cells of the T AL via NKCC2 is recycled 
back into the lumen by the K+ channel ROMK, and recessive loss of 
function mutation in this channel results in a related phenotype (Simon 
et al., 1996c). The explanation for this phenocopy is that fluid in the 
TAL is high in Na and Cl but low in K. Consequently, without the 
"recycling" of K+ entering the cell back into the lumen via ROMK (Fig. 
3.8), there is not sufficient K+ in the lumen to permit normal extraction 
of Na+ and Ct by NKCC2. Interestingly, these patients have severe salt 
wasting, but their K+ loss is much less than seen among patients with 
NKCC2 mutations. The reason for this is likely that ROMK is also used 
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Fig. 3.8. Mutations that impair salt reabsorption in the thick ascending limb of Henle 
(TAL) cause the hypotensive disease Barner syndrome. Mutations in genes that mediate 
apical entry of Na-K-2Cl, the recycling of K+ back into the lumen, or exit of c1- across 
the basolateral membrane in the T AL typically cause severe salt wasting and Barner 
syndrome. 
for K+ secretion in the distal nephron. This observation has interesting 
therapeutic implications (see below). 
NaCl entering the epithelial cell of the TAL must return to the blood­
stream by traversing the basolateral membrane. Recessive loss of function 
mutations in the c1- channel encoded by CLCNKB results in another 
subset of patients with Bartter syndrome and identifies this channel as a 
required component of this exit step (Simon et al., 1997). Interestingly, 
this channel, when expressed alone in Xenopus oocytes, is inactive, sug­
gesting the requirement for an accessory subunit. Recently, Birkenhager 
and colleagues (2002) have identified such an accessory subunit of this 
channel by idenification of mutations in the protein Barttin in another 
group of Bartter patients. 
Genotype-phenotype correlations have demonstrated that much of the 
clinical variability seen among Bartter patients is explained by the differ­
ent genes that are mutated to produce this phenotype. For example, 
patients with mutations in CLCNKB or Barttin have more modest hyper­
calciuria and less often have nephrocalcinosis, a feature that is nearly 
always found among patients with mutations in NKCC2 and ROMK. 
Patients with mutations in ROMK typically present in the neonatal 
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period with paradoxical hyperkalemia and evolve over time to hypokale­
mia that rarely requires K+ supplementation to the extent that other 
Barner patients do. 
VI. NEW PATHWAYS FROM RECENT GENETIC STUDIES 
A. A Complex Metabolic Syndrome Due to Mitochondrial Mutation
In the general population, hypertension is significantly associated with 
a number of other traits, including insulin resistance, obesity, hyperlip­
idemia, and hypomagmesemia. Together, these traits are often referred to 
as the metabolic syndrome. The mechanisms underlying the clustering of 
these traits has been unknown; however, the prevalence of this syndrome 
is recognized to affect about 25 million Americans. 
We ascertained and performed detailed clinical investigation of 142 
blood relatives of a kindred with an unusually high prevalence of hyperten­
sion, hypercholesterolemia, and hypomagnesemia (Fig. 3.9; Wilson et al., 
2004). We showed that each of these traits is strongly linked to the mater­
nal lineage in this kindred; for example, all 32 kindred members with 
clinically defined hypomagnesemia were on the same maternal lineage, a 
finding extremely unlikely to occur by chance (p = 10-9). In addition, the
fraction of offspring of affected mothers who had hypomagnesemia signifi­
cantly exceeded the number expected under autosomal dominant models 
of transmission. Elevated blood pressure and elevated LDL and VLDL 
cholesterol followed were similarly linked to the maternal lineage. 
Since mitochondria are virtually exclusively maternally transmitted in 
thousands of copies, these findings strongly implicate a mutation in the 
16-kb miwchondrial genome as the cause of this syndrome. The mito­
chondrial genome sequence revealed a novel mutation in the base imme­
diately 5' to the anticodon of the mitochondrial isoleucine tRNA. The
normal uridine at this position is perhaps the most conserved base in all
of biology, owing to the essential role of its amino group in stabilizing
the anticodon loop, permitting presentation of the anticodon to the
codon of the cognate mRNA. Uridine is found at this position in every
ile tRNA from archaebacteria to humans and is also conserved in virtually
all other tRNAs, with notable exceptions of some initiator methionine
tRNAs in eukaryotes. This mutation is homoplasmic among all members
of the maternal lineage, regardless of phenotype.
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VI 
Fig. 3.9. Kindred with mitochondrial hypomagnesemia, hypertension, and hypercho­
lesterolemia. Kindred members with hypomagnesemia, hypertension, and hypercholester­
olemia are denoted by filled symbols, the letter H and the letter C, respectively. Each of 
these traits shows a marked increase on the maternal lineage, with strong support for 
mitochondrial transmission. 
Several aspects of these findings are of interest. First, they implicate 
altered mitochondrial function in the pathogenesis of three new traits: 
hypomagnesemia, elevated blood pressure, and elevated cholesterol. This 
adds to the remarkably diverse list of traits that can result from mitochon­
drial mutation (Wallace, 1999). Second, the clustering of these pheno­
types is noteworthy: While virtually all of the clustering occurs on the 
maternal lineage, within the maternal lineage the distribution of these 
traits is nearly stochastic; this suggests that these traits are independent, 
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pleiotropic consequences of the same mitochondrial mutation. This 
observation underscores the complex patterns of clustering that can result 
from the combined effects of pleiotropy and incomplete penetrance. 
Finally, these findings raise the question of whether the loss of mitochon­
drial function that is believed to accompany aging (Petersen et al., 2003) 
may commonly contribute to the development of these traits. Interest­
ingly, other components of the metabolic syndrome, such as insulin 
resistance, have previously been linked to altered mitochondrial function, 
thereby raising the possibility that the clustered abnormalities of the 
metabolic syndrome might commonly be attributed to impaired mito­
chondrial function. 
B. Pseudohypoaldosteronism Type II-A Disease of
Disrupted Integration of Electrolyte Flux
There are hundreds of ion channels, exchangers, contransporters, 
and paracellular flux pathways distributed along the nephron. A major 
question for the biology of this complex system is how the activities 
of these diverse flux mediators are coordinated to achieve coherent 
responses to physiologic perturbation. One might hope that genetic 
approaches would identify mutations in key components of these regu­
latory networks that disrupt the normal integration of these diverse 
functions. 
Pseudohypoaldosteronism type II (PHAII) appears to define just such 
a higher-order regulator of function. PHAII features hypertension with 
hyperkalemia and metabolic acidosis despite otherwise normal renal func­
tion; it is transmitted as an autosomal dominant trait (Gordon et al., 
1995). Interestingly, the hypertension and hyperkalemia can be corrected 
by low doses of thiazide diuretics or the removal of chloride from the 
diet. 
We have identified mutations in two novel serine threonine kinases, 
Wnkl and Wnk4, as causes of PHAII (Wilson et al., 2001). Mutations 
in Wnkl are large deletions in the first intron that increase expression of 
Wnkl mRNA. Mutations in Wnk4 are missense and cluster within a 
10-amino-acid acidic segment distal to the kinase domain. The expression
of these kinases in the kidney is confined to the distal convoluted tubule
and collecting duct of the nephron. Outside the kidney, these kinases are
expressed in diverse o- transporting epithelia, including pancreatic ducts,
hepatic bile ducts, colonic crypts, and sweat ducts.
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The clinical phenotypes and localization of these kinases suggest that 
they are involved in the regulation of electrolyte flux. By expression 
studies in Xenopus oocytes and mammalian cells, we have shown that this 
is the case. W nk4 regulates the activity of at least three transport pathways 
in the distal nephron: the thiazide-sensitive NaCl cotransporter NCC 
(Wilson et al., 2004; Yang et al., 2003), the K+ channel ROMK (Kahle 
et al., 2003), and the paracellular flux pathway for c1- in the distal 
nephron (Fig. 3.10; Yamauchi et al., 2004; Kahle et al., 2004). Wild-type 
Wnk4 is a potent inhibitor of both NCC and ROMK; however, there 
are important differences in the mechanism of inhibition. First, Wnk4's 
inhibition of NCC is dependent upon its active kinase domain, whereas 
inhibition of ROMK is kinase-independent. Second, while inhibition of 
both is achieved by their reduced expression at the cell surface, inhibition 
of ROMK is dependent upon endocytosis via clathrin-coated pits, whereas 
inhibition of NCC is not. Most significantly, PHAII mutant Wnk4 has 
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Fig. 3.10. Wnk4 regulates the balance between c1- reabsorption and K+ secretion. 
Wnk4 inhibits the activity of the NaCl corransporter in the distal convoluted tubule (OCT) 
and the K+ channel ROMK in intercalated cells of the collecting duct. Mutations in WNK4 
in patients with pseudohypoaldosteronism type II (PHAII) alleviate inhibition of NCC, 
augment inhibition of ROMK, and increase paracellular Ct permeability. This results in 
a net increase in NaCl reabsorption and reduced K+ secretion. 
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increasing inhibition of ROMK. In addition, Wnk4 has effects on the 
paracellular flux pathway. When expressed under control of doxycycline 
in MDCK monolayers, expression of wild-type Wnk4 induces a selective 
increase in the absolute paracellular permeability for Ct. PHAII-mutant 
W nk4 imparts a much larger effect to increase paracellular c1-
permeability. 
These effects indicate that Wnk4 has properties of a molecular switch, 
which enable it to have independent and divergent effects on highly 
diverse flux pathways. PHAII-mutant Wnk4 is inferred to increase renal 
NaCl reabsorption by increasing the activity of NCC and by increasing 
permeability of the paracellular pathway for Ci-, allowing increased reab­
sorption of Na+ with c1- in the distal nephron and concomitantly decreas­
ing the electrical driving force to support K+ secretion. In parallel, 
PHAII-mutant Wnk4 also inhibits K+ secretion directly, by inducing 
clearance of ROMK from the cell surface. These effects of mutant Wnk4 
can therefore explain the physiology observed in patients with PHAII. 
These observations suggest that Wnk4's actions can explain a classic 
paradox in renal physiology: Aldosterone is secreted in response to hypo­
volemia via angiotensin II and also by direct effects of elevated K+ levels. 
This raises the question of how the nephron is able to appropriately dis­
tinguish these distinct stimuli, responding by maximally increasing NaCl 
reabsorption in the former state while maximizing K+ secretion in the 
latter condition. Wnk4 seems ideally poised to play a role in this decision. 
We presume that the mutations that define PHAII mimic a normal 
mechanism which sets the Wnk4 switch to promote NaCl reabsorption 
while inhibiting K+ secretion. While further work will be required to 
establish the upstream regulators of Wnk4, it is tempting to speculate 
that angiotensin II might play a role, since this hormone is a distinguish­
ing mark of hypovolemia versus hyperkalemia. 
VIL IMPLICATIONS 
A. Pathophysiology of Hypertension
These studies have unequivocally established a causal relationship 
between alteration of net renal salt reabsorption and altered blood pres­
sure in humans; mutations that increase salt balance raise blood pressure 
and mutations that reduce salt balance lower blood pressure (Fig. 3.11). 
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Fig. 3.11. Diagram of a nephron. The pathways mediating NaCl reabsorption in 
epithelial cells of the thick ascending limb of the loop of Henle (TAL), distal convoluted 
tubule (DCT), and the cortical collecting tubule (CCT) are indicated, along with the renin­
angiotensin system, the major regulator of renal salt reabsorption. Inherited diseases affect­
ing these pathways affect blood pressure and are indicated. Abbreviations: AI, angiotensin 
I; ACE, angiotensin converting enzyme; All, angiotensin II (All); MR, mineralocorcicoid 
receptor; GRA, glucocorticoid-remediable aldosteronism; PHAl, pseudohypoaldosteron­
ism, type l; AME, apparent mineralocorticoid excess; 11 �-HSD2, 11�-hydroxysteroid 
dehydrogenase-2; DOC, deoxycorticosterone; PT, proximal tubule. 
The mechanisms of this effect can readily be explained via an initial 
increase in plasma volume and cardiac output; over time, this hemody­
namic pattern is modified to one of high systemic vascular resistance by 
the local regulation .of.vascular beds to match perfusion to metabolic 
demand (Guyton, 1991). Significantly, while there are diverse effects on 
K+, Ca2+, and Mg2+ homeostasis, in these diseases the vector for NaCl 
consistently predicts the resulting effect on blood pressure. 
These observations raise the question of whether other forms of hyper­
tension also arise via increased renal salt reabsorption. The answer is 
unequivocally yes, because virtually all of the acquired forms of hyper­
tension arise via this mechanism. Aldosterone-producing adenoma is one 
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obvious example, in which constitutive aldosterone secretion leads to 
increased ENaC activity. Another is renal artery stenosis, in which 
decreased perfusion of one kidney results in reduced o- delivery to the 
macula densa and increased secretion of renin. This activation of the 
renin-angiotensin system ultimately feeds into the same final common 
pathway of increased renal salt reabsorption. Similarly, the excess cate­
chols in pheochromocytoma increase proximal renal tubular salt reabsorp­
tion and also decrease renal blood flow. Finally, consumption of large 
amounts of natural licorice produces hypertension by inhibition of an 
enzyme, I I-beta hydroxysteroid dehydrogenase, which converts cortisol 
to cortisone in principal cells of the collecting duct. Cortisol is a potent 
agonist of the mineralocorticoid receptor and in the absence of its metab­
olism to cortisone induces hypertension by activation of this receptor. 
Finally, the impaired salt clearance seen in end-stage renal disease likely 
accounts for the prevalence of hypertension among patients on dialysis; 
this fraction approaches 100% in the United States. At present, one can 
make the case that all of the known causes of hypertension act by increas­
ing net salt balance, either by altering renal salt handling directly or as a 
secondary effect resulting either from impaired blood flow to the kidney 
or from impaired glomerular filtration. 
Given that the genetic and acquired forms of hypertension act via 
altered renal salt handling, it is tempting to speculate that the common 
forms of hypertension will also arise by this mechanism with either a 
direct effect on renal salt handling or an indirect one via reduced glo­
merular filtration due to primary glomerular or renal vascular effects. 
Large population studies are underway that will address whether rare or 
common variants in genes in these pathways play a role in common forms 
of hypertension. Regardless of the answer to this latter question, however, 
the recognidon that blood pressure can be modulated from very low to 
very high levels by alteration of renal salt balance has important implica­
tions for the treatment of hypertension. 
B. Therapeutic Implications
1. Tailored Therapy for Rare Diseases. For the rare Mendelian hyperten­
sive diseases discussed above, knowledge of their pathogenesis provides
the opportunity to direct therapy to the primary underlying abnormal­
ity rather than an empiric approach. This is of clinical importance
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because without diagnosis, these patients are frequently thought to have 
refractory hypertension. For example, in the case of GRA, patients can 
be specifically treated with physiologic doses of glucocorticoids, which 
suppresses secretion of ACTH and shuts down expression of the disease­
causing chimeric gene. Other treatments that counter the effects of 
aldosterone excess, such as mineralocorticoid antagonists or inhibitors 
of ENaC, can also be effective. Similarly, patients with PHAII are 
exquisitely sensitive to thiazide diuretics, which reduce activity of the 
NaCl cotransporter whose activity is elevated in this disease. The value 
of specific therapy among these patients underscores the importance of 
diagnosing these diseases. 
2. Hypertension in ESRD. As noted above, hypertension has a prevalence
that approaches 100% among the more than 300,000 patients in the
United States on dialysis for end-stage renal disease. This high prevalence
is very likely attributable to inadequate removal of salt and water on
dialysis, a consequence of efforts to reduce the number and time of dialysis
sessions. Recent studies that employ more frequent or longer dialysis
permit more net salt and water removal; these substantiate a dramatic
reduction in the prevalence of hypertension (Chan et al., 2002) and
strongly motivate modification of dialysis practice.
3. Treatment of Essential Hypertension. These genetic studies reveal varia­
tion in renal salt handling as a key site for long-term regulation of blood
pressure in humans. Most significantly, mutations in this process impart
very large effects on the trait, demonstrating the ability of this system to
modulate blood pressure from extremely low to extremely high values.
These observations implicate renal salt handling as a key target for thera­
peutic intervention in the treatment of hypertension. This suggests that
drugs that target this pathway might be superior to agents that act on other
pathways. Recent randomized controlled trials support this notion. For
example, the 33,000-patient ALLHA T trial found that chlorthalidone, an
inhibitor of the NaCl cotransporter, was as good as or better than other
agents for all major clinical outcomes (ALLHAT Officers et al., 2002).
Similarly, the Life study, a large randomized controlled trial of the angio­
tensin II receptor blocker losartan versus a beta blocker, showed superior­
ity of losartan in prevention of stroke and overall morbid outcomes
(Dahlof et al., 2002). These findings strongly support the primary
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importance of reducing salt balance in the treatment of hypertension, 
which is now reflected in national guidelines (Chobanian et al., 2003). 
Nonetheless, it is apparent that treatment with existing single agents is 
insufficient to achieve adequate blood pressure lowering in many patients. 
One explanation for this is the interference of counter-regulatory mecha­
nisms, like the increased dietaty salt intake documented among patients 
genetically deficient for the NaCl cotransporter NCC, the target of thia­
zide diuretics (Cruz et al., 2001). These observations suggest that initial 
therapy with inhibitors of the NaCl cotransporter plus an ACE inhibitor 
or All antagonist should achieve synergistic effects; this has been substan­
tiated by clinical study. These observations argue that the long-standing 
practice of starting therapy with a single agent is flawed, and they suggest 
more rational approaches that start with synergistic combination thera­
pies; recent national consensus recommendations reflect such a change in 
approach (Chobanian et al., 2003). 
C. New (and Old) Therapeutic Targets
These findings also have implications for new therapeutic development 
for the treatment of hypertension applicable to the general population. 
The most attractive targets are those that are pharmacologically tractable 
and that induce the largest blood-pressure-lowering effects with the fewest 
side effects. The phenotype resulting from loss of a gene product is a 
strong predictor of both the efficacious and adverse effects of a pharma­
cologic inhibitor of the gene product. The finding that loss of function 
mutations in a number of ion channels and cotransporters result in 
marked salt wasting and reduced blood pressure indicates that these chan­
nels are poised at key points in integrated physiology and moreover are 
not of redundant function; these genetic findings suggest that pharmaco­
logic antagonists of these same channels and transporters would have 
potent antihypertensive diuretic effects. New targets that are predicted to 
have large effects on salt balance and blood pressure include the potassium 
channel ROMK, the chloride channel CLCNKB, and potentially the 
WNK kinases. Importantly, the paucity of clinical phenotypes in other 
organs among patients lacking these transporters and channels suggests 
that specific antagonists would not have limiting adverse effects in other 
organs. 
There are specific features of these targets that might give their antago­
nists particular utility. For example, limiting side effects of treatment with 
existing antagonists of the Na-K -2Cl cotransporter are the development 
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of marked hypokalemia and deafness at higher doses. The potassium 
channel ROMK is used for K+ recycling in the T AL and for K+ secretion 
in the collecting duct. As a result, individuals deficient for ROMK have 
massive Na+ depletion but only mild potassium wasting; their hearing is 
also normal. These findings suggest that ROMK antagonists would have 
potent diuretic effects like furosemide without the hypokalemic or loss of 
hearing side effects. These might be superior agents for treatment of 
hypertension as well as congestive heart failure. 
Finally, some channels previously thought to be poor targets have been 
resurrected by this work. Existing ENaC antagonists such as amiloride 
are typically poor antihypertensive agents, which contributed to the false 
impression that this channel normally contributes little to salt balance. 
The massive salt wasting seen in patients who are deficient in ENaC 
reveals that this channel is absolutely essential for normal salt homeostasis. 
The limited efficacy of amiloride is attributable to the action of this drug 
as a competitive antagonist for Na\ on a typical high salt diet, amiloride 
cannot effectively compete with Na+ to achieve channel antagonism. 
These considerations strongly suggest high efficacy of a potent ENaC 
antagonist; in this case the resulting volume depletion could not be com­
pensated by activation of the renin-angiotensin system, since EN aC is 
itself the means by which this compensation is achieved. Due to its role 
as the final arbiter of net Na+ reabsorption, ENaC could be the ideal 
target; nonetheless, it is presently unknown whether hyperkalemia or 
metabolic acidosis would be limiting adverse effects at higher levels of 
channel inhibition. 
D. Evolutionary Considerations
Given the strong evidence of the role of salt in the pathogenesis of 
hypertension, the role of salt in the evolutionary history of humans is 
worth considering. Sub-Saharan Africa is one of the most notoriously 
salt-poor environments on earth. It is consequently highly likely that 
genes that promoted avid salt retention were highly adaptive and strongly 
selected in mankind's ancestral environment. After the diaspora of humans 
to salt-rich environments, however, one can anticipate that those same_ 
alleles that were once adaptive lost their selective advantage and might 
indeed have become deleterious due to their promotion of hypertension 
and its morbid consequences. If this is correct, one might expect to see 
ethnic variation in the prevalence of hypertension, with those whose 
ancestors left Africa 100,000 years ago having a lower incidence of 
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hypertension than those who only recently have been exposed to a high 
salt diet. These considerations may help explain the markedly higher 
prevalence of hypertension among African Americans and other recent 
descendents of native African populations. 
One prediction of this proposal is that alleles that promote salt reten­
tion in the African population should be selected against and be reduced 
in frequency in populations that long ago left Africa. For example, vari­
ants in the angiotensinogen gene have been implicated as having modest 
but significant effects on blood pressure (Jeunemaitre et al., 1992). 
Intriguingly, the angiotensinogen allele conferring higher blood pressure 
has a frequency near 100% in native African populations (Lifton et al., 
1993) but has been reduced to only 35% in Caucasian and Japanese 
populations. 
E. Understanding the Working of Integrated Systems
An important aspect of these genetic studies is their ability to provide 
new insights into the integrated systems biology of blood pressure and 
renal salt homeostasis. For example, the NaCl cotransporter of the DCT 
normally mediates reabsorption of� 7% of the filtered salt load, whereas 
the Na+ channel ENaC is responsible for only 1-2%. It is nonetheless 
impossible to predict the impact of the loss of either of these due to the 
unknown ability of other nephron segments to compensate for the loss 
of one of these systems. Thus it is revealing that patients missing the 
NaCl cotransporter have only about 8-mmHg reduction in blood pres­
sure while patients deficient in ENaC require lifelong massive salt sup­
plementation; we infer that the loss of NCC can be compensated by 
increased activity of ENaC and/or other pathways, whereas loss of 
ENaC activity cannot be reasonably compensated. This underscores 
the role of ENaC as a key regulated step in the overall salt-retaining 
pathway. 
Second, these studies have identified the Wnk kinases as a previously 
unknown regulatory system that has divergent effects on multiple com­
ponents of the salt retaining and K+ secreting pathway. Prior to the 
identification of the role of W nk kinases in the regulation of ion flux, 
it was commonly held that the integration of function of diverse flux 
pathways was achieved indirectly, en passant, as a consequence of the 
combined effects of changing electrochemical driving forces, hemody­
namics, and tubular flow. Perhaps not surprisingly, the kidney has evolved 
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additional mechanisms to achieve more direct control over the integrated 
function of these pathways. In addition to being of interest from a systems 
biology perspective, the W nk kinase pathway represents a potentially 
interesting new target for therapeutic intervention. 
Finally, these studies also provide further insight into integrative physi­
ology by identifying secondary effects of mutations in these salt-handling 
pathways. For example, the marked effects of loss of function Na-Cl 
cotransporter mutations in producing renal Mg2+ loss and Ca2+ retention 
reveals unanticipated interrelationships between handling of salt in the 
DCT and these divalent cations that would not have been predicted from 
known physiology. The mechanisms linking genorype to phenotype in 
this case are not presently understood, but indicate a deeper relationship 
between homeostasis of salt and divalent cations than previously 
appreciated. 
VIII. CONCLUSIONS 
Genetic studies of humans with blood pressures at the extremes of the 
distribution have established that primary alteration of net renal salt 
reabsorption alters blood pressure in humans. The finding that the same 
pathway is involved in many different diseases that feature altered blood 
pressure suggests that altered renal salt handling likely underlies all forms 
of hypertension. These findings have implications for the improved selec­
tion and combination of medications to lower blood pressure. In addi­
tion, new potential therapeutic targets have been identified at which 
antagonists are likely to have improved efficacy and reduced adverse 
effects compared with current therapies. These findings promise to 
improve the treatment of hypertension and reduce its morbid outcomes. 
Finally, the utility of investigating humans with extreme blood pressure 
phenotypes to define the fundamental pathways that regulate this trait 
serves as a model for similar approaches to other common complex traits 
in humans. 
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